GI Innovation said Wednesday it and its affiliate GI Longevity have advanced to the finals of the XPRIZE Healthspan competition as their anti-aging therapy has been recognized for its potential therapeutic uses. More than 600 teams from 58 countries entered the competition, with 100 teams advancing to the semifinal round. GI Innovation was one of 40 teams selected as Milestone 1 Award recipients in the previous stage and received a $250,000 prize to support clinical development. GI Innovation's strategy centers on using its investigational immuno-oncology drug GI-102 at an ultra-low dose to reverse immunosenescence, or the age-related decline in immune function. The approach combines low-dose GI-102 with GIB-7, a probiotic developed by GI Longevity, aiming to improve gut health, muscle function and physical activity alongside immune function.